Atea Pharmaceuticals Stock Performance
| AVIR Stock | USD 3.14 0.05 1.62% |
The firm shows a Beta (market volatility) of -0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Atea Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Atea Pharmaceuticals is likely to outperform the market. At this point, Atea Pharmaceuticals has a negative expected return of -0.11%. Please make sure to confirm Atea Pharmaceuticals' skewness, and the relationship between the total risk alpha and day median price , to decide if Atea Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Atea Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's forward indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
Five Day Return (1.57) | Year To Date Return (8.19) | Ten Year Return (89.65) | All Time Return (89.65) |
1 | Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference | 11/26/2024 |
2 | Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus | 12/04/2024 |
3 | Acquisition by Lucidi Bruno of 29600 shares of Atea Pharmaceuticals subject to Rule 16b-3 | 12/06/2024 |
4 | Atea Pharmaceuticals engages Evercore to explore partnerships | 12/16/2024 |
5 | Disposition of 33150 shares by Lucidi Bruno of Atea Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
6 | Acquisition by Duncan Barbara Gayle of 29600 shares of Atea Pharmaceuticals subject to Rule 16b-3 | 12/30/2024 |
7 | Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/08/2025 |
8 | Disposition of 15000 shares by Berger Franklin M of Atea Pharmaceuticals at 3.1923 subject to Rule 16b-3 | 01/15/2025 |
9 | Disposition of 10000 shares by Berger Franklin M of Atea Pharmaceuticals at 3.3614 subject to Rule 16b-3 | 01/16/2025 |
10 | Acquisition by Foster Wayne of 8000 shares of Atea Pharmaceuticals subject to Rule 16b-3 | 01/31/2025 |
11 | February 2025 US Penny Stocks To Watch - Simply Wall St | 02/06/2025 |
12 | Insider Trading | 02/20/2025 |
| Begin Period Cash Flow | 188.7 M |
Atea |
Atea Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 342.00 in Atea Pharmaceuticals on November 28, 2024 and sell it today you would lose (28.00) from holding Atea Pharmaceuticals or give up 8.19% of portfolio value over 90 days. Atea Pharmaceuticals is currently does not generate positive expected returns and assumes 2.7532% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Atea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atea Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atea Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atea Pharmaceuticals, and traders can use it to determine the average amount a Atea Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0397
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AVIR |
Estimated Market Risk
| 2.75 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Atea Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atea Pharmaceuticals by adding Atea Pharmaceuticals to a well-diversified portfolio.
Atea Pharmaceuticals Fundamentals Growth
Atea Stock prices reflect investors' perceptions of the future prospects and financial health of Atea Pharmaceuticals, and Atea Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atea Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (214.5 M) | ||||
| Shares Outstanding | 84.46 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.58 X | ||||
| Price To Sales | 1.90 X | ||||
| Gross Profit | (78.28 M) | ||||
| EBITDA | (119.59 M) | ||||
| Net Income | (135.96 M) | ||||
| Cash And Equivalents | 684.48 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.4 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.46 X | ||||
| Book Value Per Share | 5.43 X | ||||
| Cash Flow From Operations | (85.39 M) | ||||
| Earnings Per Share | (2.07) X | ||||
| Market Capitalization | 265.21 M | ||||
| Total Asset | 594.97 M | ||||
| Retained Earnings | (195.84 M) | ||||
| Working Capital | 558.08 M | ||||
| Current Asset | 97.88 M | ||||
| Current Liabilities | 6.25 M | ||||
About Atea Pharmaceuticals Performance
Assessing Atea Pharmaceuticals' fundamental ratios provides investors with valuable insights into Atea Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Atea Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.28) | (0.27) |
Things to note about Atea Pharmaceuticals performance evaluation
Checking the ongoing alerts about Atea Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atea Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atea Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (135.96 M) with loss before overhead, payroll, taxes, and interest of (78.28 M). | |
| Atea Pharmaceuticals currently holds about 684.48 M in cash with (85.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Atea Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Atea Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atea Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Atea Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atea Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atea Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atea Pharmaceuticals' stock. These opinions can provide insight into Atea Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.